Correct... You can see who the moles are today, tr
Post# of 148185
The eIND and CD10 data is being collected by the MHRA in anticipation of the CD12 interim results... EAMS is very much on the table.
Quote:
Great post from other board- EAMS in U.K still very likely. EAMS is similar to FDA EAU - this is why they requested the additional data of the 60+ EIND if they see a bigger benefit than risk than they will most likely approve for EAMS Early Access medicines Scheme- they will be submitting data ASAP to U.K for consideration. With this possible U.K. funding I would presume